FDA Accepts Supplement for OLUMIANT (Baricitinib) by Eli Lilly
The FDA has accepted a supplemental application for OLUMIANT (Baricitinib) from Eli Lilly.
Asset / Drug
Drug and asset intelligence for OLUMIANT with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
JAK Inhibitor
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.